Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Notes underwriting agrmnt
|
|
NEUROPATHIX, INC. (KLFE)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/12/2022 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 06/13/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/23/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/16/2022 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 01/07/2022 |
4
| PETKANAS DEAN (CEO) has filed a Form 4 on NEUROPATHIX, INC.|
Txns:
| Sold 89,000 shares
@ $0.047, valued at
$4.2k
Sold 120,000 shares
@ $0.051, valued at
$6.1k
Sold 41,000 shares
@ $0.046, valued at
$1.9k
Gifted 300,000 shares
@ $0
Gifted 250,000 shares
@ $0 |
|
| 11/12/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
| 09/28/2021 |
8-K
| Quarterly results |
| 08/06/2021 |
10-Q
| Quarterly Report for the period ended June 30, 2021 |
| 08/02/2021 |
4
| PETKANAS DEAN (CEO) has filed a Form 4 on NEUROPATHIX, INC.|
Txns:
| Granted 1,875,000 shares
@ $0.048, valued at
$90k
|
|
| 07/06/2021 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 06/23/2021 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 05/13/2021 |
10-Q
| Quarterly Report for the period ended March 31, 2021 |
| 03/30/2021 |
10-K
| Annual Report for the period ended December 31, 2020 |
| 03/18/2021 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 03/18/2021 |
4/A
| KIKIS THOMAS EVANGELOS (Chief Communication Officer) has filed a Form 4 on NEUROPATHIX, INC.|
Txns:
| Granted 800,000 options to buy
@ $0.13, valued at
$104k
|
|
| 03/17/2021 |
8-K
| Quarterly results |
| 03/16/2021 |
4
| MALASEK ROBERT (Director) has filed a Form 4 on NEUROPATHIX, INC.|
Txns:
| Granted 600,000 options to buy
@ $0.13, valued at
$78k
|
|
| 03/16/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/16/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/16/2021 |
4
| Corrao Mark (CFO) has filed a Form 4 on NEUROPATHIX, INC.|
Txns:
| Granted 800,000 options to buy
@ $0.13, valued at
$104k
|
|
| 03/16/2021 |
4
| KIKIS THOMAS EVANGELOS (Chief Communication Officer) has filed a Form 4 on NEUROPATHIX, INC.|
Txns:
| Granted 800,000 options to buy
@ $0.13, valued at
$104k
|
|
| 03/16/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/16/2021 |
4
| KINNEY WILLIAM (Chief Scientific Officer) has filed a Form 4 on NEUROPATHIX, INC.|
Txns:
| Granted 900,000 options to buy
@ $0.13, valued at
$117k
|
|
| 02/23/2021 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 02/23/2021 |
8-K
| Quarterly results |
| 12/21/2020 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat... |
| 11/19/2020 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits |
| 11/12/2020 |
10-Q
| Quarterly Report for the period ended September 30, 2020 |
| 11/06/2020 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits |
| 10/05/2020 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 09/22/2020 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 09/22/2020 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 08/12/2020 |
10-Q
| Quarterly Report for the period ended June 30, 2020 |
|
|
|